942400-51-3

Basic information

• Product Name: (3R,5S)-3,5-DIMETHYLMORPHOLINE
• Synonyms: (3R,5S)-3,5-DIMETHYLMORPHOLINE
• CAS NO: 942400-51-3
• Molecular Formula: C6H13NO
• Molecular Weight: 115.17352
• Mol File: 942400-51-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 150.805°C at 760 mmHg
• Flash Point: 50.079°C
• Appearance: /
• Density: 0.863g/cm³
• Vapor Pressure: 3.775mmHg at 25°C
• Refractive Index: 1.406
• CAS DataBase Reference: (3R,5S)-3,5-DIMETHYLMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,5S)-3,5-DIMETHYLMORPHOLINE(942400-51-3)
• EPA Substance Registry System: (3R,5S)-3,5-DIMETHYLMORPHOLINE(942400-51-3)

Safety Data

• Hazardous Substances Data: 942400-51-3(Hazardous Substances Data)

Usage

General Description

(3R,5S)-3,5-Dimethylmorpholine is a heterocyclic organic compound that belongs to the class of morpholine derivatives. It is a chiral molecule with two asymmetric carbon atoms, resulting in four possible stereoisomers. This particular isomer, denoted as (3R,5S), is a colorless, viscous liquid at room temperature. It is commonly used as a reagent in organic synthesis, particularly in the production of pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique structure and reactivity make it a valuable building block in the synthesis of various compounds. Additionally, it is known to exhibit some biological activity and is being investigated for potential pharmaceutical applications.

InChI:InChI=1/C6H13NO/c1-5-3-8-4-6(2)7-5/h5-7H,3-4H2,1-2H3/t5-,6+

Upstream product

• 154634-95-4 (3S,5S)-4-tert-butoxycarbonyl-3,5-dimethylmorpholine 
• 55556-87-1 N-nitroso-trans-2,6-dimethylmorpholine 
• 154596-18-6 (3S,5R)-4-tert-butoxycarbonyl-3,5-dimethylmorpholine 
• 55556-87-1 N-nitroso-cis-2,6-dimethylmorpholine 
• 110-98-5 1,1'-oxydipropan-2-ol 
• 313974-82-2 4-(3,5-dimethylmorpholin-4-yl)benzonitrile 
• 6168-72-5 2-Amino-1-propanol 
• 116-09-6 hydroxy-2-propanone 
• 2294-46-4 bis(2-hydroxy-1-methylethyl)amine 

Downstream Products

• 1042907-05-0 C₃₆H₃₆F₂N₆O₄ 
• 1334524-00-3 8-(((3R,5S)-3,5-dimethylmorpholino)methyl)-5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one 
• 938443-23-3 7-chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine 
• 1605317-96-1 (2R,5S)-5-((3R,5R)-3,5-dimethyl-morpholin-4-ylmethyl)-4-(2-{6-[(4-fluoro-phenyl)-(S)-hydroxy-methyl]-3,3-dimethyl-2,3-dihydro-pyrrolo[3,2-b]pyridin-1-yl}-2-oxo-ethyl)-2-methyl-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Steric effects in the catalytic amination of γ-, δ-, and ε-glycols

The amination of butane-1,4-diol, isomeric dipropylene glycols, and cyclohexane-1,4-diyldimethanol in the presence of nickel/copper/chromium catalysts has been studied. The effect of the initial glycol structure on the reaction selectivity has been estima

Quinoxaline compounds

Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

Imidazole derivatives

The present invention relates to the imidazole derivative of the following formula (I) wherein R1 is hydrogen, optionally substituted alkyl and the like, R2 is hydrogen, optionally substituted alkyl and the like, R3is optionally substituted heteroaryl, R4 is optionally substituted cycloalkyl, optionally substituted phenyl and the like, provided that when R1 is hydrogen, and R2 and R4 are the same or different and each is phenyl or phenyl substituted by halogen atom, lower alkyl or lower alkoxy, R3 is benzothiazolyl or thiazolyl substituted by phenyl, the imidazole derivative of the following formula (XII) wherein R6 is optionally substituted phenyl or optionally substituted heteroaryl and R7 is substituted phenyl, and pharmaceutically acceptable salts thereof. The compounds of the formulas (I) and (XII) and pharmaceutically acceptable salts thereof of the present invention inhibit IL-4 and IL-5 production by Th2 cells and are effective for the prophylaxis and treatment of allergic diseases such as atopic dermatitis, bronchial asthma, allergic rhinitis and the like.